To provide a ceramic particle separable composite material having a calcium phosphate sintered body particle with which bioaffinity reduction and solubility change are suppressed as much as possible and which has a smaller particle diameter. A ceramic particle separable composite material comprising a ceramic particle and a substrate, wherein: the ceramic particle and the substrate are chemically bonded to each other, or the ceramic particle physically adheres to or is embedded in the substrate; the ceramic particle has a particle diameter within a range of 10 nm to 700 nm; the ceramic particle is a calcium phosphate sintered body particle; and the ceramic particle contains no calcium carbonate.

To provide a ceramic particle separable composite material having a calcium phosphate sintered body particle with which bioaffinity reduction and solubility change are suppressed as much as possible and which has a smaller particle diameter. A ceramic particle separable composite material comprising a ceramic particle and a substrate, wherein: the ceramic particle and the substrate are chemically bonded to each other, or the ceramic particle physically adheres to or is embedded in the substrate; the ceramic particle has a particle diameter within a range of 10 nm to 700 nm; the ceramic particle is a calcium phosphate sintered body particle; and the ceramic particle contains no calcium carbonate.

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

This invention provides a measure that makes it possible to prevent more effectively, in comparison with the prior art, the invasion of germs from the gap between a dental prosthesis and the gingiva when the dental prosthesis is used in an oral cavity as well as the infection and inflammation associated therewith.

There is a dental prosthesis or a component thereof, characterized in that: the dental prosthesis or the component thereof has hydroxyapatite fine particles on a surface of the dental prosthesis or the component thereof; the hydroxyapatite fine particles are sintered bodies; and the hydroxyapatite fine particles have a mean particle size of 10 to 1,000 nm.

This invention provides a measure that makes it possible to prevent more effectively, in comparison with the prior art, the invasion of germs from the gap between a dental prosthesis and the gingiva when the dental prosthesis is used in an oral cavity as well as the infection and inflammation associated therewith.

There is a dental prosthesis or a component thereof, characterized in that: the dental prosthesis or the component thereof has hydroxyapatite fine particles on a surface of the dental prosthesis or the component thereof; the hydroxyapatite fine particles are sintered bodies; and the hydroxyapatite fine particles have a mean particle size of 10 to 1,000 nm.

A method for preparing a sterilized scaffold for medical use, the method comprising the steps of: i) Loading collagen to a fiber mesh containing fibers of polylactide polymer or copolymer (commonly denoted PLA) to obtain a PLA-collagen scaffold, ii) Drying the PLA-collagen scaffold obtained from step i), iii) Sterilizing the PLA-collagen scaffold obtained from the drying step ii) to obtain the sterilized scaffold.

The sterilized scaffold obtained has improved biomechanical properties compared with an unsterilized scaffold.

A mechanoactive material includes a composite textile that includes a textile substrate formed from a plurality of fibers assembled in a fiber assembly pattern and a material deposited via an additive manufacturing technique onto and/or between the fibers of the textile substrate based on an additive manufacturing pattern. The composite textile includes at least one prestress and/or residual stress and/or exhibits a change in at least one mechanical property, material property, or structure in response to at least one endogenous and/or exogenous stimulus.

A mechanoactive material includes a composite textile that includes a textile substrate formed from a plurality of fibers assembled in a fiber assembly pattern and a material deposited via an additive manufacturing technique onto and/or between the fibers of the textile substrate based on an additive manufacturing pattern. The composite textile includes at least one prestress and/or residual stress and/or exhibits a change in at least one mechanical property, material property, or structure in response to at least one endogenous and/or exogenous stimulus.

The present disclosure provides patterned biomaterials having organized cords and extracellular matrix embedded in a 3D scaffold. According, the present disclosure provides compositions and applications for patterned biomaterials. Pre-patterning of these biomaterials can lead to enhanced integration of these materials into host organisms, providing a strategy for enhancing the viability of engineered tissues by promoting vascularization.